Author:
Heffernan Aaron James,Sime Fekade Bruck,Naicker Saiyuri,Andrews Katherine,Ellwood David,Guerra-Valero Yarmarly,Wallis Steven,Lipman Jeffrey,Grimwood Keith,Roberts Jason Alexander
Funder
National Health and Medical Research Council
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference44 articles.
1. Bayer Ltd. Phase III study program with amikacin inhale in addition to standard of care in intubated and mechanically ventilated patients with gram-negative pneumonia does not meet primary endpoint of superiority [17th March 2019]. Availablehttps://media.bayer.com/baynews/baynews.nsf/id/en-doccheck-disclaimer?OpenDocument&dcp=Phase-III-study-program-Amikacin-Inhale-addition-standard-intubated-mechanically-ventilated-patients&pi=2017-0360&ccm=.
2. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis;Barclay;J Antimicrob Chemother,1996
3. Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia;Bodem;Am J Respir Dis,1983
4. The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases;Bataillon;J Antimicrob Chemother,1992
5. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs;Borgatta;Eur J Clin Microbiol Infect Dis,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献